CAR T-cell Therapy in 2025: Evidence, Safety, and Patient Selection

Update: 2025-09-24

Description

Sponsored by Bristol Myers Squibb.

Hosted on Acast. See acast.com/privacy for more information.

Comments

In Channel

$Prise en charge des patients atteints de LLC doublement exposée et réfractaire.$

Prise en charge des patients atteints de LLC doublement exposée et réfractaire.

2025-11-1816:48

$Addressing the management of patients with double exposed and refractory CLL$

Addressing the management of patients with double exposed and refractory CLL

2025-11-1817:40

CAR T-cell Therapy in 2025: Evidence, Safety, and Patient Selection

2025-09-2424:35

Practical considerations in the management of early rrMM in the Canadian context

2025-01-0632:00

The role of selinexor in early rrMM and sequencing in 2024.

2024-06-2627:34

00:00

#box-pro-ellipsis-176590080906538{-webkit-line-clamp:2;}CAR T-cell Therapy in 2025: Evidence, Safety, and Patient Selection